Enhancing Patient Care in PPF: Strategies for Addressing Unmet Needs and Optimizing Treatment Approaches : Episode 7

Potential Impact of Emerging PPF Treatments on Patient Outcomes and Health Ccare Resource Utilization

January 28, 2025

By Anna-Maria Hoffmann-Vold, M.D., Ph.D.

Opinion

Video

Panelists discuss the potential role of emerging treatments in the progressive pulmonary fibrosis (PPF) landscape if approved, exploring how they could address key unmet needs, improve patient outcomes, and optimize healthcare resource utilization.

EP: 1.Understanding PPF and Its Risk Factors

EP: 2.PPF Symptoms and Impact on Quality of Life

EP: 3.Diagnosing PPF and the Importance of Early Detection

EP: 4.Current Treatment Approaches for PPF: Pharmacological and Nonpharmacological

EP: 5.Key Unmet Needs in PPF Management

EP: 6.Emerging Therapies for PPF

Now Viewing

EP: 7.Potential Impact of Emerging PPF Treatments on Patient Outcomes and Health Ccare Resource Utilization

EP: 8.Enhancing Patient Care in Progressive Pulmonary Fibrosis: Strategies for Addressing Unmet Needs and Optimizing Treatment Approaches

Video content above is prompted by the following:

What is the potential role of these emerging treatments in the PPF landscape if approved, and how might they address key unmet needs, improve patient outcomes, and optimize healthcare resource utilization?

Related Content

Enhancing Patient Care in Progressive Pulmonary Fibrosis: Strategies for Addressing Unmet Needs and Optimizing Treatment Approaches

Peter Wehrwein, Managing Editor

March 5th 2025

Article

Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria Hoffmann-Vold, M.D., Ph.D., of Oslo University Hospital and the expert featured on this MHE K-Cast.

Value-Based Decision-Making in Metastatic Breast Cancer

Ian E. Krop, MD, PhD;Debra Patt, MD, PhD, MBA

September 16th 2021

Article

In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.